[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account

Is MRD Negativity the End Goal? Understanding When/Why It's Important

Is MRD Negativity the End Goal? Understanding When/Why It's Important image

Is MRD Negativity the End Goal? Understanding When/Why It's Important

Minimal Residual Disease (MRD)
event Feb 23, 2023 / 07:00PM - 08:00PM EST
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

Many of you are familiar with the basic concept of MRD, and perhaps some feel the "pressure" to get to MRD negativity. But should all regimens' end goal be to achieve MRD negativity? And if MRD negativity is not achieved with the initial treatment, but the patient is in complete response, should the therapy be adjusted to achieve MRD negativity? This type of question will be answered by myeloma specialist, Dr. Marc Braunstein. Join us as we learn together.

Schedule & Agenda

The panelist Audrey Burton-Bethke
Introductions
07:00PM
Audrey Burton-Bethke

Audrey introduces the agenda of the event and featured speaker Dr.  Marc Braunstein.

The panelist Marc Braunstein, MD, PhD
Presentation
07:05PM
Marc Braunstein, MD, PhD

Dr. Marc Braunstein talks about MRD negativity.

person
Questions and Answers
07:35PM
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators

The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio
The panelist Marc Braunstein, MD, PhD
Marc Braunstein, MD, PhD

Marc Barunstein, MD, PhD is a board-certified hematologist/oncologist with a long-standing interest in plasma cell disorders. He is a part of the NYU Perlmutter Cancer Center's multiple myeloma and cellular therapy programs and serve as Associate Professor of Medicine at NYU Grossman Long Island School of Medicine where he co-direct the medical school hematology curriculum and also serves as Director of the hematology/oncology fellowship program. His clinical research focus is on the use of novel immunotherapy combinations to treat multiple myeloma. As part of his role, he also focuses on medical education and serves on education committees for the American Society of Hematology and American Society of Clinical Oncology, as well as volunteer committees with the American Society of Clinical Oncology and American College of Physicians. In his free time he volunteers with the Leukemia and Lymphoma Society, spends time with his family, and enjoys playing guitar and mandolin.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

newsletter icon

Get the latest thought leadership on your Multiple Myeloma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
Pfizer
Genentech
Regeneron
Adaptive

Follow Us

facebook instagram linkedin tiktok youtube